focus -WSS

focus

author：Wikipedia 2025-09-30 18:54:03 - browse：4799

Photo illustration of Chris Viehbacher -- biotech coverage from STAT — Chris Viehbacher took over as Biogen CEO in November. Suzanne Kreiter/Globe staff; Photo illustration Alex Hogan/STAT

This was supposed to be the new Biogen. When Chris Viehbacher, a respected pharmaceutical executive, took over as CEO in November, Wall Street saw him as a steadying force for the wayward company and a strong personality who would stand up to its quarrelsome board.

Instead, Biogen’s board has saddled Viehbacher with the first crisis of his tenure at the company. Alex Denner, a long-time director, nominated a biotech executive who is also the mother of his child to succeed him on the board, and Biogen chose not to disclose the couple’s relationship to shareholders, an omission that shocked people close to the company and undermined the notion that Biogen was changing for the better.

“It’s just disappointing to see after all the criticism that has been levied at the company over the last few years, there really seems to be no self-awareness going into this recommendation,” said Brian Skorney, a securities analyst at Baird who covers Biogen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： NIH study of ME/CFS points to clear biological hallmarks

explore

WSS

Telehealth startups are trying to fill the menopause care vacuum

Why palliative psychiatry is worth discussing

A new nitrogen execution bill also undermines medical licensing

A solution to the after

A new nitrogen execution bill also undermines medical licensing

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

focus

focus

hotspot

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

A new ‘biological computer' targets cancer while sparing healthy cells

As demand for Covid shots wanes, Moderna seeks its next success

PBM reform efforts get punted in Congress

Supreme Court strikes down use of affirmative action

A solution to the after

After affirmative action ruling, medical educators look to 'holistic review'

Alabama hospital puts IVF treatments on hold

Moonlake's readout produced a cash windfall. Risks remain

Sanders wants to replace patents with prizes for drug inventions

Wikipedia

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Antivenom research: Lessons from HIV applied in search for universal antidote

After a decade, new Gardasil ad campaign gets it (mostly) right

Thousands of UK hospital doctors walk out in the latest pay dispute, crippling health services

Alabama IVF ruling threatens families facing fatal genetic disease

Medicare inequities exacerbate Puerto Rico’s health disparities

hotspot

hotspot

explore

focus